title: Recent progress in mucosal vaccine development: potential and limitations.
abstract: Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are much needed. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and great expectations for new mucosal vaccines lie ahead. Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines.
authors: Center for Mucosal Immunobiology and Vaccines (MIVAC), Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden. nils.lycke@microbio.gu.se
authors: Nils
authors: N
authors: Lycke
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D009092:Mucous Membrane / Q000276:immunology*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014612:Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; D022243:Rotavirus Vaccines; D014612:Vaccines